Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
samedi, octobre 31
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Aardvark Therapeutics Inc
AARD
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.36
-0.08
-5.56%
Dern. MÀJ: Oct 30, 7:41 PM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Aardvark Therapeutics Financials
Aardvark Therapeutics (AARD) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share
Benzinga Newsdesk
Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran— AMTD Digital, Aardvark, MongoDB In Focus
U.S. stock futures fell sharply on Monday following Friday’s losses. Futures of the major benchmark indices were negative amid the ongoing Iran-U.S. conflict.
Rishabh Mishra
PRO
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share
Benzinga Newsdesk
PRO
Aardvark Therapeutics Q2 EPS $(0.66) Misses $(0.61) Estimate
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.61) by 7.67 percent. This is a 51.82 percent increase over losses of $(1.37) per share
Benzinga Newsdesk
